S&P 500   3,373.43 (-0.20%)
DOW   27,896.72 (-0.29%)
QQQ   272.48 (+0.23%)
AAPL   459.73 (+1.70%)
MSFT   208.60 (-0.28%)
FB   261.30 (+0.54%)
GOOGL   1,516.65 (+0.62%)
AMZN   3,160.60 (-0.05%)
NVDA   457.50 (-0.02%)
CGC   17.34 (+0.52%)
BABA   253.70 (-0.58%)
TSLA   1,623.75 (+4.44%)
GE   6.60 (-1.79%)
MU   46.13 (-4.85%)
AMD   81.84 (-0.93%)
T   29.91 (-0.89%)
F   7.03 (-1.13%)
ACB   10.18 (+3.88%)
GILD   68.20 (-0.93%)
NFLX   481.46 (+1.26%)
DIS   130.97 (-0.62%)
BAC   26.35 (-1.42%)
BA   174.40 (-0.59%)
S&P 500   3,373.43 (-0.20%)
DOW   27,896.72 (-0.29%)
QQQ   272.48 (+0.23%)
AAPL   459.73 (+1.70%)
MSFT   208.60 (-0.28%)
FB   261.30 (+0.54%)
GOOGL   1,516.65 (+0.62%)
AMZN   3,160.60 (-0.05%)
NVDA   457.50 (-0.02%)
CGC   17.34 (+0.52%)
BABA   253.70 (-0.58%)
TSLA   1,623.75 (+4.44%)
GE   6.60 (-1.79%)
MU   46.13 (-4.85%)
AMD   81.84 (-0.93%)
T   29.91 (-0.89%)
F   7.03 (-1.13%)
ACB   10.18 (+3.88%)
GILD   68.20 (-0.93%)
NFLX   481.46 (+1.26%)
DIS   130.97 (-0.62%)
BAC   26.35 (-1.42%)
BA   174.40 (-0.59%)
S&P 500   3,373.43 (-0.20%)
DOW   27,896.72 (-0.29%)
QQQ   272.48 (+0.23%)
AAPL   459.73 (+1.70%)
MSFT   208.60 (-0.28%)
FB   261.30 (+0.54%)
GOOGL   1,516.65 (+0.62%)
AMZN   3,160.60 (-0.05%)
NVDA   457.50 (-0.02%)
CGC   17.34 (+0.52%)
BABA   253.70 (-0.58%)
TSLA   1,623.75 (+4.44%)
GE   6.60 (-1.79%)
MU   46.13 (-4.85%)
AMD   81.84 (-0.93%)
T   29.91 (-0.89%)
F   7.03 (-1.13%)
ACB   10.18 (+3.88%)
GILD   68.20 (-0.93%)
NFLX   481.46 (+1.26%)
DIS   130.97 (-0.62%)
BAC   26.35 (-1.42%)
BA   174.40 (-0.59%)
S&P 500   3,373.43 (-0.20%)
DOW   27,896.72 (-0.29%)
QQQ   272.48 (+0.23%)
AAPL   459.73 (+1.70%)
MSFT   208.60 (-0.28%)
FB   261.30 (+0.54%)
GOOGL   1,516.65 (+0.62%)
AMZN   3,160.60 (-0.05%)
NVDA   457.50 (-0.02%)
CGC   17.34 (+0.52%)
BABA   253.70 (-0.58%)
TSLA   1,623.75 (+4.44%)
GE   6.60 (-1.79%)
MU   46.13 (-4.85%)
AMD   81.84 (-0.93%)
T   29.91 (-0.89%)
F   7.03 (-1.13%)
ACB   10.18 (+3.88%)
GILD   68.20 (-0.93%)
NFLX   481.46 (+1.26%)
DIS   130.97 (-0.62%)
BAC   26.35 (-1.42%)
BA   174.40 (-0.59%)
Log in

NASDAQ:RAREUltragenyx Pharmaceutical News Headlines

$85.83
+2.02 (+2.41 %)
(As of 08/13/2020 04:00 PM ET)
Add
Compare
Today's Range
$84.18
Now: $85.83▼
$86.94
50-Day Range
$73.52
MA: $82.16▼
$90.00
52-Week Range
$31.99
Now: $85.83▼
$91.77
Volume14,186 shs
Average Volume545,984 shs
Market Capitalization$5.20 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.22

Headlines

Ultragenyx Pharmaceutical (NASDAQ RARE) News Headlines

Source:
DateHeadline
Ultragenyx Pharmaceutical (NASDAQ:RARE) Given Hold Rating at Credit Suisse GroupUltragenyx Pharmaceutical (NASDAQ:RARE) Given Hold Rating at Credit Suisse Group
marketbeat.com - July 31 at 4:30 PM
Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) Director Clay B. Siegall Sells 23,404 SharesUltragenyx Pharmaceutical Inc (NASDAQ:RARE) Director Clay B. Siegall Sells 23,404 Shares
americanbankingnews.com - August 11 at 2:12 PM
Did Hedge Funds Make The Right Call On Ultragenyx Pharmaceutical Inc (RARE)Did Hedge Funds Make The Right Call On Ultragenyx Pharmaceutical Inc (RARE)
finance.yahoo.com - August 10 at 5:57 PM
Did Hedge Funds Make The Right Call On Ultragenyx Pharmaceutical Inc (RARE) ?Did Hedge Funds Make The Right Call On Ultragenyx Pharmaceutical Inc (RARE) ?
finance.yahoo.com - August 10 at 12:56 PM
Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) Receives Average Recommendation of "Buy" from BrokeragesUltragenyx Pharmaceutical Inc (NASDAQ:RARE) Receives Average Recommendation of "Buy" from Brokerages
americanbankingnews.com - August 9 at 2:22 PM
Ultragenyx Pharmaceutical (NASDAQ:RARE) Receives "Hold" Rating from Credit Suisse GroupUltragenyx Pharmaceutical (NASDAQ:RARE) Receives "Hold" Rating from Credit Suisse Group
www.americanbankingnews.com - July 31 at 5:26 PM
Ultragenyx Pharmaceutical Inc. 2020 Q2 - Results - Earnings Call PresentationUltragenyx Pharmaceutical Inc. 2020 Q2 - Results - Earnings Call Presentation
seekingalpha.com - July 31 at 4:47 PM
Ultragenyx (RARE) Loss Narrows Y/Y & Revenues Beat EstimatesUltragenyx (RARE) Loss Narrows Y/Y & Revenues Beat Estimates
finance.yahoo.com - July 31 at 2:39 PM
Ultragenyx Pharmaceutical (NASDAQ:RARE) PT Lowered to $87.00 at Morgan StanleyUltragenyx Pharmaceutical (NASDAQ:RARE) PT Lowered to $87.00 at Morgan Stanley
www.americanbankingnews.com - July 31 at 10:19 AM
Barclays Reaffirms Overweight Rating for Ultragenyx Pharmaceutical (NASDAQ:RARE)Barclays Reaffirms Overweight Rating for Ultragenyx Pharmaceutical (NASDAQ:RARE)
www.americanbankingnews.com - July 31 at 7:37 AM
Ultragenyx (RARE) Reports Q2 Loss, Tops Revenue EstimatesUltragenyx (RARE) Reports Q2 Loss, Tops Revenue Estimates
finance.yahoo.com - July 31 at 12:05 AM
Achondroplasia Treatment Market Seeking Excellent Growth | Ribomic, BioMarin Pharmaceutical, Ascendis PharmaAchondroplasia Treatment Market Seeking Excellent Growth | Ribomic, BioMarin Pharmaceutical, Ascendis Pharma
www.marketwatch.com - July 30 at 9:03 AM
Ultragenyx Pharmaceutical Q2 2020 Earnings PreviewUltragenyx Pharmaceutical Q2 2020 Earnings Preview
seekingalpha.com - July 29 at 6:59 PM
Ultragenyx Pharmaceutical (RARE) Set to Announce Quarterly Earnings on ThursdayUltragenyx Pharmaceutical (RARE) Set to Announce Quarterly Earnings on Thursday
www.americanbankingnews.com - July 25 at 10:08 AM
Ultragenyx to Host Conference Call for Second Quarter 2020 Financial Results and Corporate UpdateUltragenyx to Host Conference Call for Second Quarter 2020 Financial Results and Corporate Update
www.marketwatch.com - July 24 at 1:42 PM
Ultragenyx to Host Conference Call for Second Quarter 2020 Financial Results and Corporate UpdateUltragenyx to Host Conference Call for Second Quarter 2020 Financial Results and Corporate Update
finance.yahoo.com - July 24 at 1:42 PM
Arcturus Therapeutics Announces Agreement with Israeli Ministry of Health to Supply COVID-19 Vaccine Candidate, LUNAR-COV19Arcturus Therapeutics Announces Agreement with Israeli Ministry of Health to Supply COVID-19 Vaccine Candidate, LUNAR-COV19
finance.yahoo.com - July 23 at 5:32 PM
Analysts Set Expectations for Ultragenyx Pharmaceutical Incs FY2020 Earnings (NASDAQ:RARE)Analysts Set Expectations for Ultragenyx Pharmaceutical Inc's FY2020 Earnings (NASDAQ:RARE)
www.americanbankingnews.com - July 23 at 7:57 AM
$40.28 Million in Sales Expected for Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) This Quarter$40.28 Million in Sales Expected for Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) This Quarter
www.americanbankingnews.com - July 23 at 2:28 AM
UltraGenyx launches triheptanoin in U.S. for rare metabolic disordersUltraGenyx launches triheptanoin in U.S. for rare metabolic disorders
seekingalpha.com - July 22 at 10:35 AM
Ultragenyx Announces U.S. Commercial Launch of Dojolvi™ (triheptanoin), the First FDA-Approved Therapy for the Treatment of Long-chain Fatty Acid Oxidation DisordersUltragenyx Announces U.S. Commercial Launch of Dojolvi™ (triheptanoin), the First FDA-Approved Therapy for the Treatment of Long-chain Fatty Acid Oxidation Disorders
finance.yahoo.com - July 22 at 10:35 AM
FY2024 EPS Estimates for Ultragenyx Pharmaceutical Inc Increased by Analyst (NASDAQ:RARE)FY2024 EPS Estimates for Ultragenyx Pharmaceutical Inc Increased by Analyst (NASDAQ:RARE)
www.americanbankingnews.com - July 22 at 8:37 AM
-$1.56 EPS Expected for Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) This Quarter-$1.56 EPS Expected for Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) This Quarter
www.americanbankingnews.com - July 21 at 9:24 PM
Ultragenyx Pharmaceutical Reaches Analyst Target PriceUltragenyx Pharmaceutical Reaches Analyst Target Price
www.nasdaq.com - July 2 at 1:07 PM
Ultragenyx (RARE) Looks Good: Stock Adds 8.2% in SessionUltragenyx (RARE) Looks Good: Stock Adds 8.2% in Session
finance.yahoo.com - July 2 at 1:07 PM
Ultragenyxs Dojolvi Gets FDA Nod to Treat Rare DiseaseUltragenyx's Dojolvi Gets FDA Nod to Treat Rare Disease
www.nasdaq.com - July 1 at 2:39 PM
Ultragenyx's Dojolvi Gets FDA Nod to Treat Rare DiseaseUltragenyx's Dojolvi Gets FDA Nod to Treat Rare Disease
finance.yahoo.com - July 1 at 2:39 PM
Ultragenyx gets second FdA approval in JuneUltragenyx gets second FdA approval in June
finance.yahoo.com - July 1 at 9:38 AM
Ultragenyx Announces U.S. FDA Approval of Dojolvi™ (UX007/triheptanoin), the First FDA-Approved Therapy for the Treatment of Long-chain Fatty Acid Oxidation DisordersUltragenyx Announces U.S. FDA Approval of Dojolvi™ (UX007/triheptanoin), the First FDA-Approved Therapy for the Treatment of Long-chain Fatty Acid Oxidation Disorders
finance.yahoo.com - June 30 at 6:23 PM
Ultragenyx Gets FDA Nod for Label Expansion of CrysvitaUltragenyx Gets FDA Nod for Label Expansion of Crysvita
www.nasdaq.com - June 19 at 3:11 PM
FDA grants a second approval to Ultragenyx drug for rare diseaseFDA grants a second approval to Ultragenyx drug for rare disease
finance.yahoo.com - June 19 at 10:11 AM
Ultragenyx and Kyowa Kirin Announce U.S. FDA Approval of Crysvita(R) (burosumab) for the Treatment of Tumor-Induced Osteomalacia (TIO)Ultragenyx and Kyowa Kirin Announce U.S. FDA Approval of Crysvita(R) (burosumab) for the Treatment of Tumor-Induced Osteomalacia (TIO)
www.marketwatch.com - June 18 at 6:21 PM
FDA OKs Ultragenyxs Crysvita for bone-softening disorderFDA OKs Ultragenyx's Crysvita for bone-softening disorder
seekingalpha.com - June 18 at 6:21 PM
A rare win: North Bay biotech gets FDA approval for drug to treat bone diseaseA rare win: North Bay biotech gets FDA approval for drug to treat bone disease
www.bizjournals.com - June 18 at 6:21 PM
Ultragenyx Pharmaceutical: Near-Term Catalysts Offer Best Of Both WorldsUltragenyx Pharmaceutical: Near-Term Catalysts Offer Best Of Both Worlds
seekingalpha.com - June 16 at 12:26 PM
The Week Ahead In Biotech: FDA Decisions In The Cards For Merck, Epizyme, Evoke And UltragenyxThe Week Ahead In Biotech: FDA Decisions In The Cards For Merck, Epizyme, Evoke And Ultragenyx
www.benzinga.com - June 14 at 12:54 PM
Utragenyx Shares Soar Above 60% YTD on Pipeline DevelopmentsUtragenyx Shares Soar Above 60% YTD on Pipeline Developments
finance.yahoo.com - June 11 at 12:05 PM
Why Is Ultragenyx (RARE) Up 10.7% Since Last Earnings Report?Why Is Ultragenyx (RARE) Up 10.7% Since Last Earnings Report?
finance.yahoo.com - June 5 at 1:16 PM
Ultragenyx to Present at Upcoming Investor ConferencesUltragenyx to Present at Upcoming Investor Conferences
www.benzinga.com - May 28 at 8:39 AM
Advanced gene therapies pose new questionsAdvanced gene therapies pose new questions
www.bizjournals.com - May 22 at 9:53 AM
Ultragenyx Announces Positive Longer-term Results from First Three Cohorts of Phase 1/2 Study of DTX301 Gene Therapy in Ornithine Transcarbamylase (OTC) DeficiencyUltragenyx Announces Positive Longer-term Results from First Three Cohorts of Phase 1/2 Study of DTX301 Gene Therapy in Ornithine Transcarbamylase (OTC) Deficiency
finance.yahoo.com - May 13 at 4:28 PM
Analyst Estimates: Heres What Brokers Think Of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) After Its First-Quarter ReportAnalyst Estimates: Here's What Brokers Think Of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) After Its First-Quarter Report
finance.yahoo.com - May 11 at 5:23 PM
Analyst Estimates: Here's What Brokers Think Of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) After Its First-Quarter ReportAnalyst Estimates: Here's What Brokers Think Of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) After Its First-Quarter Report
finance.yahoo.com - May 11 at 5:23 PM
Ultragenyx to Present at BofA Securities Global Health Care ConferenceUltragenyx to Present at BofA Securities Global Health Care Conference
finance.yahoo.com - May 11 at 5:23 PM
The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The SpotlightThe Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight
feeds.benzinga.com - May 10 at 3:53 PM
Ultragenyx (RARE) Q1 Earnings & Sales Fall Short of EstimatesUltragenyx (RARE) Q1 Earnings & Sales Fall Short of Estimates
finance.yahoo.com - May 8 at 4:42 PM
Ultragenyx (RARE) Reports Q1 Loss, Lags Revenue EstimatesUltragenyx (RARE) Reports Q1 Loss, Lags Revenue Estimates
finance.yahoo.com - May 7 at 4:06 PM
Ultragenyx (RARE) Q1 Earnings & Sales Fall Short of EstimatesUltragenyx (RARE) Q1 Earnings & Sales Fall Short of Estimates
finance.yahoo.com - May 7 at 4:06 PM
Edited Transcript of RARE earnings conference call or presentation 6-May-20 9:00pm GMTEdited Transcript of RARE earnings conference call or presentation 6-May-20 9:00pm GMT
finance.yahoo.com - May 7 at 4:06 PM
Ultragenyx Pharmaceutical Inc (RARE) Q1 2020 Earnings Call TranscriptUltragenyx Pharmaceutical Inc (RARE) Q1 2020 Earnings Call Transcript
finance.yahoo.com - May 7 at 4:06 PM
Will Ultragenyx Pharmaceutical Continue to Surge Higher?Will Ultragenyx Pharmaceutical Continue to Surge Higher?
finance.yahoo.com - May 6 at 3:57 PM
This page was last updated on 8/13/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.